Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Nick Thatcher, Kevin Carroll, Tudor–Eliade Ciuleanu et al.|The Lancet|2005Cited by 2.1k
P1.01-28 Impact of Afatinib Dosing on Safety and Efficacy Real-World in Patients with EGFR Mutation-Positive Advanced NSCLCBalázs Halmos, Enric Carcereny, E.H. Tan et al.|Journal of Thoracic Oncology|2018Cited by 1